About Us

Verve Therapeutics was created with a singular focus: to protect the world from heart disease

Our Mission

Verve is focused on discovering and developing medicines that safely edit the adult genome and mimic naturally protective gene variants to treat coronary heart disease, the leading cause of death worldwide.

Verve brings together two of the biggest breakthroughs in 21st century biomedicine — human genetic analysis and gene editing — to realize a new future, one of longevity and vitality for tens of millions of people around the globe with or at risk for cardiovascular disease.

Verve Team

Verve has been purpose-built for the task ahead, with a founding team of world-leading experts in cardiovascular medicine, human genetics, gene editing delivery technology and safety, and drug development.

 

Adelman, Burt, M.D.
Burt Adelman, M.D.
Co-Founder and Chairman of the Board
Amaonye, Michael
Michael Amaonye
Research Associate
Ashe, Andrew, J.D.
Andrew Ashe, J.D.
President and Chief Operating Officer
Beach, Aaron
Aaron Beach
Principal Scientist, Analytical Chemistry
Beaudoin, Maggie
Maggie Beaudoin
Senior Director, Finance
Bellinger, Andrew, M.D., Ph.D.
Andrew Bellinger, M.D., Ph.D.
Chief Scientific Officer
Biswas, Souvik, Ph.D.
Souvik Biswas, Ph.D.
Senior Scientist
Braun, Maurine
Maurine Braun
Senior Manager, Preclinical Operations and Toxicology
Chadwick, Alexandra, Ph.D.
Alexandra Chadwick, Ph.D.
Associate Director, Preclinical Research and Development
Chen, Huei-Mei
Huei-Mei Chen, Ph.D.
Senior Scientist, Gene Editing
Cheng, Christopher J., Ph.D.
Christopher J. Cheng, Ph.D.
Director, RNA Technology and Manufacturing
Clendaniel, Victoria
Victoria Clendaniel
Research Associate
Cook, Angela
Angela Cook
Chief of Staff
Dembla, Ishwin
Ishwin Dembla
Senior Scientist, Analytical Chemistry
DeNizio, Jamie, Ph.D.
Jamie DeNizio, Ph.D.
Scientist
Dutta, Chaitali, Ph.D.
Chaitali Dutta, Ph.D.
Principal Scientist, Pharmacology and Toxicology
Eisner, Robin
Robin Eisner
Administrative and Operations Manager
El-Gamal, Yasser
Yasser (Yas) El-Gamal
Vice President, Legal Affairs and Chief Intellectual Property Counsel
Fuselli, Nancy
Nancy Fuselli
Director, Quality Affairs
Ganey, Jack
Jack Ganey
Associate Scientist
Gangopadhyay, Soumya
Soumya Gangopadhyay, Ph.D.
Senior Scientist, Bioassays and Editing
Garcia, Sara, Ph.D.
Sara Garcia, Ph.D.
Senior Scientist, Computational Biology
Garrity, Ryan
Ryan Garrity
Senior In Vivo/In Vitro Research Associate
Gichuru, Kevin
Kevin Gichuru
Accounting Manager
Glass, Zachary
Zachary Glass
Scientist, Formulation
Greenfield, Matthew
Matthew Greenfield
Associate Director, Laboratory Operations
Iyer, Sowmya
Sowmya Iyer, Ph.D.
Senior Scientist, Computational Biology
Joung, J. Keith, M.D., Ph.D.
J. Keith Joung, M.D., Ph.D.
Co-Founder
Kasiewicz, Lisa, Ph.D.
Lisa Kasiewicz, Ph.D.
Scientist
Kathiresan, Sekar, M.D.
Sekar Kathiresan, M.D.
Co-Founder, Chief Executive Officer and Board Member
Kirk, Jaime
Jaime Kirk
Senior Manager, Technical Accounting
Lavoie, Jennifer
Jennifer Lavoie
Associate Director, CMC Program Management
Li, Jimmy
Jimmy Li
Staff Accountant
Madsen, James
James Madsen, Ph.D.
Associate Director, Mass Spectrometry
Malyala, Padma
Padma Malyala
Executive Director, Formulation and Characterization
Matsumoto, Yuri
Yuri Matsumoto, Ph.D.
Principal Scientist, Bioanalytical and Translational Sciences
Mazzola, Anne Marie
Anne Marie Mazzola
Study Coordinator and Scientist, Pharmacology and Toxicology
Mizoguchi, Taiji, Ph.D.
Taiji Mizoguchi, Ph.D.
Scientist
Musunuru, Kiran, M.D., Ph.D., MPH
Kiran Musunuru, M.D., Ph.D., MPH
Co-Founder and Senior Scientific Advisor
Nagpal, Ash
Ash Nagpal
Senior Process Engineer
Naigles, Robyn
Robyn Naigles
Administrative and Operations Associate
Nasrullah, Yusuf
Yusuf Nasrullah
Scientist
Nneji, Joseph
Joseph Nneji
Senior Research Associate
O’Neil, April
April O'Neil
Associate Director, Human Resources
Philippakis, Anthony, M.D., Ph.D.
Anthony Philippakis, M.D., Ph.D.
Co-Founder and Board Member
Platt, Colin
Colin Platt
Scientist, In Vivo Pharmacology
Powell, Brent V.
Brent V. Powell, Ph.D.
Scientist
Rajeev, Kallanthottathil G., Ph.D.
Kallanthottathil G. Rajeev, Ph.D.
Vice President, CMC
Reiss, Caroline, Ph.D.
Caroline Reiss, Ph.D.
Senior Scientist, RNA Technology and Manufacturing
Ren, Huilan
Huilan Ren
Associate Scientist
Rohde, Ellen, Ph.D.
Ellen Rohde, Ph.D.
Vice President, Pharmacology and Toxicology
Rozen, Issi, MBA
Issi Rozen, MBA
Co-Founder and Strategic Advisor
Sanjeev, Athul
Athul Sanjeev
Research Associate
Shatzer, Wynn
Wynn Shatzer
Research Associate
Shay, Maddy
Maddy Shay
Research Associate, Formulation and Characterization
Stahley, Mary
Mary Stahley, Ph.D.
Associate Principal Scientist, Process Development and Technology Transfer
Stolz, Leslie, Ph.D.
Leslie Stolz, Ph.D.
Vice President, Regulatory Affairs
Street, Lynnsey
Lynnsey Street
Associate Scientist
Ticho, Barry, M.D., Ph.D.
Barry Ticho, M.D., Ph.D.
Co-Founder
Vafai, Scott
Scott Vafai, M.D.
Executive Director, Translational Medicine
Wang, Kui, Ph.D.
Kui Wang, Ph.D.
Senior Scientist

Board of Directors

Adelman, Burt, M.D.
Burt Adelman, M.D.
Co-Founder and Chairman of the Board
Alston, Jessica, Ph.D.
Jessica Alston, Ph.D.
Board Observer
Casdin, Eli
Eli Casdin, MBA
Board Observer
Evans, John, MBA
John Evans, MBA
Board Member
Kathiresan, Sekar, M.D.
Sekar Kathiresan, M.D.
Co-Founder, Chief Executive Officer and Board Member
Nikolic, Boris, M.D.
Boris Nikolic, M.D.
Board Observer
Philippakis, Anthony, M.D., Ph.D.
Anthony Philippakis, M.D., Ph.D.
Co-Founder and Board Member
Yeshwant, Krishna, M.D., MBA
Krishna Yeshwant, M.D., MBA
Board Member

Scientific Advisory Board

Braunwald, Eugene
Eugene Braunwald, M.D.
Geall, Andrew
Andrew Geall, Ph.D.
Heaton, Penny
Penny M. Heaton, M.D.
Rader, Daniel
Daniel J. Rader, M.D.

Collaborations and Licensing

Verve has assembled a portfolio of gene editing and delivery technologies through strategic collaborations and licensing agreements with industry leaders, including Beam Therapeutics, the Broad Institute and Harvard University.

Investors

Verve is supported by a top-tier syndicate of investors who share our vision for tackling the world’s most urgent health challenge.